1 insider bought shares over the last 90 days, the latest filed 08 Oct 2026.
Rayan is a listed company. Filings by its managers are published through AMF. 2 insiders have disclosed 11 filings since 18 October 2025.
Open-market activity splits into 8 purchases and 3 sales; 1 insider sit on the buying side and 1 insider on the selling side. The amount is not disclosed for 11 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
For context, the typical company on the same exchange (median of 27 companies) published 4 filings over the same period, against 11 filings here. Over the whole record (from 2026), the tally stands at 8 purchases and 3 sales.
The last purchase on record was published on 8 October 2026, which is 10 days ago.
Source: insider filings from AMF. Past trades are no guide to future returns.
Analysts rate Rayan Hold (neutral), based on 4 analysts. Average price target: QAR 2.12.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
Rayan is a company operating in the health product and pharmaceutical distribution sector. It is active in the DSMD market.